Jeffrey Wing

Prof. Jeffrey Wing

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2011 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
RMRavi S. Menon
Ravi S. Menon
RBRichard E. Burgess
Richard E. Burgess
JWJeffrey Wing
Jeffrey Wing
MGM. Christopher Gibbons
M. Christopher Gibbons
NSNawar M. Shara
Nawar M. Shara
CKChelsea S. Kidwell
Chelsea S. Kidwell

14 May 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ESEmily C Somers
Emily C Somers
WZWenpu Zhao
Wenpu Zhao
ELEmily E. Lewis
Emily E. Lewis
LWLu Wang
Lu Wang
JWJeffrey Wing
Jeffrey Wing
MKMariana J. Kaplan
Mariana J. Kaplan
Systemic lupus erythematosus (SLE) patients have a striking increase in cardiovascular (CV) comorbidity not fully explained by the Framingham risk score. Recent evidence from in vitro studies suggests that type I interferons (IFN) could promote premature CV disease (CVD) in SLE. We assessed the association of type I IFN signatures with functional and anatomical evidence of vascular damage, and with biomarkers of CV risk in a cohort of lupus patients without overt CVD. Serum type I IFN activity (induction of five IFN-inducible genes; IFIGs) from 95 SLE patient and 38 controls was quantified by real-time PCR. Flow mediated dilatation (FMD) of the brachial artery and carotid intima media thickness (CIMT) were quantified by ultrasound, and coronary calcification by computed tomography. Serum vascular biomarkers were measured by ELISA. We evaluated the effect of type I IFNs on FMD, CIMT and coronary calcification by first applying principal components analysis to combine data from five IFIGs into summary components that could be simultaneously modeled. Three components were derived explaining 97.1% of the total IFIG variation. Multivariable linear regression was utilized to investigate the association between the three components and other covariates, with the outcomes of FMD and CIMT; zero-inflated Poisson regression was used for modeling of coronary calcification. After controlling for traditional CV risk factors, enhanced serum IFN activity was significantly associated with decreased endothelial function in SLE patients and controls (p<0.05 for component 3), increased CIMT among SLE patients (p<0.01 for components 1 and 2), and severity of coronary calcification among SLE patients (p<0.001 for component 3). Type I IFNs are independently associated with atherosclerosis development in lupus patients without history of overt CVD and after controlling for Framingham risk factors. This study further supports the hypothesis that type I IFNs promote premature vascular damage in SLE.

1 August 2011 in Stroke
Verified
Journal Article
Closed access
PDF file
AHAmie W. Hsia
Amie W. Hsia
DEDorothy F. Edwards
Dorothy F. Edwards
LMLewis B. Morgenstern
Lewis B. Morgenstern
JWJeffrey Wing
Jeffrey Wing
NBNina C. Brown
Nina C. Brown
CKChelsea S. Kidwell
Chelsea S. Kidwell
Background and Purpose—: Some prior studies have shown that racial disparities exist in intravenous tissue plasminogen activator (tPA) use for acute ischemic stroke. We sought to determine whether race was associated with tPA treatment for stroke in a predominantly black urban population. Methods—: Systematic chart abstraction was performed on consecutive hospitalized patients with ischemic stroke from all 7 acute care hospitals in the District of Columbia from February 1, 2008, to January 31, 2009. Results—: Of 1044 patients with ischemic stroke, 74% were black, 19% non-Hispanic white, and 5% received intravenous tPA. Blacks were one third less likely than whites to receive intravenous tPA (3% versus 10%, P <0.001). However, blacks were also less likely than whites to present within 3 hours of symptom onset (13% versus 21%, P =0.004) and also less likely to be tPA-eligible (5% versus 13%, P <0.001). Of those who presented within 3 hours, blacks were almost half as likely to be treated with intravenous tPA than whites (27% versus 46%, P =0.023). The treatment rate for tPA-eligible patients was similar for blacks and whites (70% versus 76%, P =0.62). Conclusions—: In this predominantly black urban population hospitalized for acute ischemic stroke, blacks were significantly less likely to be treated with intravenous tPA due to contraindications to treatment, delayed presentation, and stroke severity. Effective interventions designed to increase treatment in this population need to focus on culturally relevant education programs designed to address barriers specific to this population.

1 September 2013 in Stroke
Verified
Journal Article
Closed access
PDF file
BOBruce Ovbiagele
Bruce Ovbiagele
JWJeffrey Wing
Jeffrey Wing
RMRavi S. Menon
Ravi S. Menon
RBRichard E. Burgess
Richard E. Burgess
MGM. Christopher Gibbons
M. Christopher Gibbons
CKChelsea S. Kidwell
Chelsea S. Kidwell
Background and Purpose—: To investigate the relationship between chronic kidney disease (CKD) and MRI-defined cerebral microbleeds (CMB), a harbinger of future intracerebral hemorrhage (ICH), among patients with a recent history of primary ICH. Methods—: Using data from a predominantly black cohort of patients with a recent ICH-enrolled in an observational study between September 2007 and June 2011, we evaluated the association between CKD (defined as estimated low glomerular filtration rate<60 mL/min per 1.73 m 2 ) and CMB on gradient-echo MRI. Multivariable models were generated to determine the contribution of CKD to the presence, number, and location of CMB. Results—: Of 197 subjects with imaging data, mean age was 59 years, 48% were women, 73% were black, 114 (58%) had ≥1 CMBs, and 52 (26%) had CKD. Overall, CKD was associated with presence of CMB (adjusted odds ratio, 2.70; 95% confidence interval [CI], 1.10–6.59) and number of CMB (adjusted relative risk, 2.04; 95% CI, 1.27–3.27). CKD was associated with CMB presence (adjusted odds ratio, 3.44; 95% CI, 1.64–7.24) and number (adjusted relative risk, 2.46; 95% CI, 1.11–5.42) in black patients, but not CMB presence (adjusted odds ratio, 3.00; 95% CI, 0.61–14.86) or number (adjusted relative risk, 1.03; 95% CI: 0.22–4.89) in non-Hispanic white patients (interactions by race were statistically not significant). Conclusions—: CKD is associated with a greater presence and number of CMB in ICH patients, particularly in patients of black race. Future studies should assess whether low estimated glomerular filtration rate may be a CMB risk marker or potential therapeutic target for mitigating the development of CMB.

1 March 2011 in Sleep Medicine
Verified
Journal Article
Closed access
ASAnna Svatikova
Anna Svatikova
RCRonald D. Chervin
Ronald D. Chervin
JWJeffrey Wing
Jeffrey Wing
BSBrisa N. Sanchez
Brisa N. Sanchez
EMErin M. Migda
Erin M. Migda
DBDevin L. Brown
Devin L. Brown

1 April 2012 in Gender Medicine
Verified
Journal Article
Closed access
SSShawnita Sealy-Jefferson
Shawnita Sealy-Jefferson
JWJeffrey Wing
Jeffrey Wing
BSBrisa N. Sánchez
Brisa N. Sánchez
DBDevin L. Brown
Devin L. Brown
WMWilliam J. Meurer
William J. Meurer
LLLynda D. Lisabeth
Lynda D. Lisabeth